肝细胞癌
队列
医学
接收机工作特性
放射科
内科学
作者
Rex Wan‐Hin Hui,K.W. Chiu,I-Cheng Lee,Chenlu Wang,Ho Ming Cheng,Jian‐Liang Lu,Xianhua Mao,Sarah N. Yu,Lok-Ka Lam,Lung‐Yi Mak,Tan To Cheung,Nam-Hung Chia,Chin‐Cheung Cheung,W. Kan,Tiffany Wong,Albert C. Y. Chan,Yi-Hsiang Huang,Man‐Fung Yuen,Philip L. H. Yu,Wai‐Kay Seto
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2024-12-02
被引量:1
标识
DOI:10.1097/hep.0000000000001180
摘要
Background: Hepatocellular carcinoma (HCC) recurrence frequently occurs after curative surgery. Histological microvascular-invasion (MVI) predicts recurrence but cannot provide pre-operative prognostication, whereas clinical prediction scores have variable performances. Methods: Recurr-NET, a multimodal multiphasic residual-network random survival forest deep-learning model incorporating pre-operative CT and clinical parameters, was developed to predict HCC recurrence. Pre-operative triphasic CT scans were retrieved from patients with resected histology-confirmed HCC from four centers in Hong Kong (Internal-cohort). The internal-cohort was randomly divided in an 8:2 ratio into training and internal-validation. External-testing was performed in an independent cohort from Taiwan. Results: Among 1231 patients (Age 62.4, 83.1% male, 86.8% viral hepatitis, median follow-up 65.1 months), cumulative HCC recurrence at years 2 and 5 were 41.8% and 56.4% respectively. Recurr-NET achieved excellent accuracy in predicting recurrence from years 1-5 (Internal cohort AUROC 0.770-0.857; External AUROC 0.758-0.798), significantly out-performing MVI (Internal AUROC 0.518-0.590; External AUROC 0.557-0.615) and multiple clinical risk scores (ERASL-PRE, ERASL-POST, DFT, and Shim scores) (Internal AUROC 0.523-0.587, External AUROC: 0.524-0.620) respectively (all p <0.001). Recurr-NET was superior to MVI in stratifying recurrence risks at year 2 (Internal: 72.5% vs. 50.0% in MVI; External: 65.3% vs. 46.6% in MVI) and year 5 (Internal: 86.4% vs. 62.5% in MVI; External: 81.4% vs. 63.8% in MVI) (all p <0.001). Recurr-NET was also superior to MVI in stratifying liver-related and all-cause mortality (all p <0.001). The performance of Recurr-NET remained robust in subgroup analyses. Conclusion: Recurr-NET accurately predicted HCC recurrence, out-performing MVI and clinical prediction scores respectively, highlighting its potential in pre-operative prognostication.
科研通智能强力驱动
Strongly Powered by AbleSci AI